RET重排肺癌脑转移发生率与多激酶抑制剂疗效
该研究基于全球多中心注册队列(A组n=114)和双机构数据集(B组n=71)分析RET重排IV期肺癌患者,发现诊断时脑转移频率为25%(95%CI 18%-32%), lifetime患病率46%(95%CI 34%-58%),多激酶抑制剂治疗脑转移患者的中位无进展生存期仅2.1个月(95%CI 1.3-2.9),颅内应答率低,提示需新型RET靶向策略。
要点
- RET重排IV期肺癌诊断时脑转移频率25%,lifetime患病率46%。
- 多激酶抑制剂治疗脑转移患者中位PFS仅2.1个月(95%CI 1.3-2.9)。
- B组颅内应答率18%(2/11),中位总体PFS 3.9个月。
核心结论
- RET重排肺癌脑转移发生频繁,多激酶抑制剂总体疗效欠佳,需新型RET靶向治疗策略。
研究设计与样本
- 全球多中心注册队列A组n=114和双机构数据集B组n=71,纳入局部检测RET重排的IV期肺癌患者。
主要发现
- 两组合并诊断时脑转移频率25%(95%CI 18%-32%),有纵向数据者lifetime患病率46%(95%CI 34%-58%)。
- RET、ROS1、ALK重排肺癌脑转移累积发生率差异显著(p=0.0039),RET居中。
- A组脑转移患者多激酶抑制剂(cabozantinib、vandetanib或sunitinib)中位PFS 2.1个月(95%CI 1.3-2.9,n=10)。
- B组11例接受cabozantinib、vandetanib(±everolimus)、ponatinib或alectinib治疗者颅内应答2例(18%),中位总体PFS 3.9个月(95%CI 2.0-4.9)。
临床怎么用
- RET重排肺癌患者应关注脑转移筛查与监测。
- 多激酶抑制剂对颅内病灶控制有限,需考虑新型RET靶向治疗或临床研究。
局限性
- A组缺乏颅内应答数据。
- B组颅内应答样本量小(n=11)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In ret proto-oncogene (RET)-rearranged lung cancers, data on the frequency of brain metastases and, in particular, the outcomes of multikinase inhibitor therapy in patients with intracranial disease are not well characterized. METHODS: A global, multi-institutional registry (cohort A, n = 114) and a bi-institutional data set (cohort B, n = 71) of RET-rearranged lung cancer patients were analyzed. Patients were eligible if they had stage IV lung cancers harboring a RET rearrangement by local testing. The incidence of brain metastases and outcomes with multikinase inhibitor therapy were determined. RESULTS: The frequency of brain metastases at the time of diagnosis of stage IV disease was 25% (95% confidence interval [CI]: 18%-32%) in all patients from both cohorts. The lifetime prevalence of brain metastasis in stage IV disease was 46% (95% CI: 34%-58%) in patients for whom longitudinal data was available. The cumulative incidence of brain metastases was significantly different (p = 0.0039) between RET-, ROS1-, and ALK receptor tyrosine kinase (ALK)-rearranged lung cancers, with RET intermediate between the other two groups. Although intracranial response data was not available in cohort A, the median progression-free survival of multikinase inhibitor therapy (cabozantinib, vandetanib, or sunitinib) in patients with brain metastases was 2.1 months (95% CI: 1.3-2.9 months, n = 10). In cohort B, an intracranial response was observed in 2 of 11 patients (18%) treated with cabozantinib, vandetanib (± everolimus), ponatinib, or alectinib; the median overall progression-free survival (intracranial and extracranial) was 3.9 months (95% CI: 2.0-4.9 months). CONCLUSIONS: Brain metastases occur frequently in RET-rearranged lung cancers, and outcomes with multikinase inhibitor therapy in general are suboptimal. Novel RET-directed targeted therapy strategies are needed.
引用
- Drilon A, Lin JJ, Filleron T, et al. Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers. J Thorac Oncol. 2018. PMID: 30017832. doi:10.1016/j.jtho.2018.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。